| Abstrakt: |
A recent study conducted at Tufts Medical Center in Boston, Massachusetts explored the use of dual immune checkpoint inhibitor (ICI) therapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC). The study found that dual ICI therapy improved overall survival in patients who did not respond to treatment, but not in those who did respond. Additionally, the therapy increased time to progression in patients with bone metastases and squamous histology. The researchers concluded that further studies are needed to develop an optimal treatment-selection strategy for untreated mNSCLC. [Extracted from the article] |
